76756
document
Acipimox in the treatment of patients with hyperlipidaemia : a double blind trial . Fifty-two patients with Fredrickson Type IIb or Type IV hyperlipidaemia , in whom diet had not achieved satisfactory lipid levels , completed a double blind randomised study of acipimox versus placebo . The patients were given acipimox , 250 mg three times daily or placebo for a three month period , and plasma lipids and glucose were monitored . The patients receiving acipimox showed a fall in the mean concentration of plasma triglyceride compared to placebo ( 0.74 mmol/l ) and this was most marked in patients whose initial plasma triglyceride levels were greater than 3 mmol/l ( 1.0 mmol/l , confidence limits 0.18 , 1.82 ) . Acipimox was well tolerated , and could be a useful addition to the drugs available for the treatment of patients with hypertriglyceridaemia .
76757
Intervention_Pharmacological
Acipimox
76758
Intervention_Pharmacological
acipimox
76759
Intervention_Control
placebo .
76760
Intervention_Pharmacological
acipimox
76761
Intervention_Control
placebo
76762
Outcome_Physical
plasma lipids and glucose
76763
Outcome_Physical
plasma triglyceride
76764
Outcome_Physical
plasma triglyceride levels
76765
Outcome_Other
tolerated
76766
Participant_Condition
hyperlipidaemia
76767
Participant_Sample-size
Fifty-two
76768
Participant_Condition
Fredrickson Type IIb or Type IV hyperlipidaemia
76769
Participant_Condition
hypertriglyceridaemia